Daniel Andrés Colón Ríos
MD-PhD StudentAbout
Research
Publications
2025
Correction: Harnessing ExDNA for precision Exatecan delivery in cancer: a novel antibody-drug conjugate approach
Ianniello Z, Lu H, Quijano E, Colón-Ríos D, Rackear M, Bommireddy V, Ludwig D, Shen Z, Glazer P. Correction: Harnessing ExDNA for precision Exatecan delivery in cancer: a novel antibody-drug conjugate approach. Molecular Cancer 2025, 24: 304. PMID: 41339893, PMCID: PMC12673787, DOI: 10.1186/s12943-025-02539-9.Commentaries, Editorials and LettersHarnessing exDNA for precision exatecan delivery in cancer: a novel antibody-drug conjugate approach
Ianniello Z, Lu H, Quijano E, Colón-Ríos D, Rackear M, Bommireddy V, Ludwig D, Shen Z, Glazer P. Harnessing exDNA for precision exatecan delivery in cancer: a novel antibody-drug conjugate approach. Molecular Cancer 2025, 24: 253. PMID: 41077566, PMCID: PMC12516839, DOI: 10.1186/s12943-025-02462-z.Peer-Reviewed Original ResearchPARP inhibitor resistance in IDH1-mutant cancers due to loss of end protection factors, 53BP1 and REV7
Colón-Ríos D, Dow J, Krysztofiak A, Liu Y, Rogers F, Glazer P. PARP inhibitor resistance in IDH1-mutant cancers due to loss of end protection factors, 53BP1 and REV7. NAR Cancer 2025, 7: zcaf047. PMID: 41357766, PMCID: PMC12675010, DOI: 10.1093/narcan/zcaf047.Peer-Reviewed Original ResearchThis study investigates how IDH1-mutant cancers develop resistance to PARP inhibitors through loss of end protection factors, 53BP1 and REV7, and shows that the drug cediranib can overcome this resistance, highlighting potential therapeutic strategies for improving cancer treatment outcomes.
2024
Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition
Rackear M, Quijano E, Ianniello Z, Colón-Ríos D, Krysztofiak A, Abdullah R, Liu Y, Rogers F, Ludwig D, Dwivedi R, Bleichert F, Glazer P. Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition. Oncotarget 2024, 15: 699-713. PMID: 39352803, PMCID: PMC11444335, DOI: 10.18632/oncotarget.28651.Peer-Reviewed Original Research
2021
Vulnerability of IDH1-Mutant Cancers to Histone Deacetylase Inhibition via Orthogonal Suppression of DNA Repair
Dow J, Krysztofiak A, Liu Y, Colon-Rios DA, Rogers FA, Glazer PM. Vulnerability of IDH1-Mutant Cancers to Histone Deacetylase Inhibition via Orthogonal Suppression of DNA Repair. Molecular Cancer Research 2021, 19: 2057-2067. PMID: 34535560, PMCID: PMC8642278, DOI: 10.1158/1541-7786.mcr-21-0456.Peer-Reviewed Original ResearchDirect targeting of amplified gene loci for proapoptotic anticancer therapy
Kaushik Tiwari M, Colon-Rios DA, Tumu HCR, Liu Y, Quijano E, Krysztofiak A, Chan C, Song E, Braddock DT, Suh HW, Saltzman WM, Rogers FA. Direct targeting of amplified gene loci for proapoptotic anticancer therapy. Nature Biotechnology 2021, 40: 325-334. PMID: 34711990, PMCID: PMC8930417, DOI: 10.1038/s41587-021-01057-5.Peer-Reviewed Original Research